scholarly journals Treatment of Cannabinoid Hyperemesis Syndrome-Associated Nausea with Haloperidol: A Case Report

2021 ◽  
Vol 10 (06) ◽  
pp. 168-175
Author(s):  
Pamela Moye-Dickerson ◽  
Anastasiya Phillips ◽  
Derek Allen Tovar
2014 ◽  
Vol 12 (1-2) ◽  
pp. 65-67 ◽  
Author(s):  
C. L. Iacopetti ◽  
C. D. Packer

Salud Mental ◽  
2017 ◽  
Vol 40 (3) ◽  
pp. 129-135
Author(s):  
Luis Fernando García-Frade Ruiz ◽  
◽  
Rodrigo Marín-Navarrete ◽  
Emmanuel Solís Ayala ◽  
Ana de la Fuente-Martín ◽  
...  

Background. The first case report on the Cannabinoid hyperemesis syndrome (CHS) was registered in 2004. Years later, other research groups complemented the description of CHS, adding that it was associated with such behaviors as chronic cannabis abuse, acute episodes of nausea, intractable vomiting, abdominal pain and compulsive hot baths, which ceased when cannabis use was stopped. Objective. To provide a brief review of CHS and report the first documented case of CHS in Mexico. Method. Through a systematic search in PUBMED from 2004 to 2016, a brief review of CHS was integrated. For the second objective, CARE clinical case reporting guidelines were used to register and manage a patient with CHS at a high specialty general hospital. Results. Until December 2016, a total of 89 cases had been reported worldwide, although none from Latin American countries. Discussion and conclusions. Despite the cases reported in the scientific literature, experts have yet to achieve a comprehensive consensus on CHS etiology, diagnosis and treatment. The lack of a comprehensive, standardized CHS algorithm increases the likelihood of malpractice, in addition to contributing to the patient’s biopsychosocial deterioration and raising care costs.


2020 ◽  
Vol 185 (9-10) ◽  
pp. e1894-e1896
Author(s):  
Rory Stuart ◽  
John Ray Richards

Abstract Cannabinoid hyperemesis syndrome presents with abdominal pain, nausea, and intractable vomiting caused by phytogenic and synthetic cannabinoid use. Complications associated with this disorder range from severe dehydration to acute kidney injury and rhabdomyolysis. This syndrome mimics many acute surgical and emergency medical conditions and can present several diagnostic and treatment challenges. While this syndrome is increasingly recognized as a common clinical entity in civilian emergency departments, there is little data concerning experience at military hospitals. We present a case of cannabinoid hyperemesis syndrome that was diagnosed and treated in a combat-zone US military emergency department in Southwest Asia.


2020 ◽  
Vol 73 (4) ◽  
Author(s):  
Stephen Lee-Cheong ◽  
Amrita Grewal ◽  
Lukas Hestvik ◽  
Reza Rafizadeh ◽  
Christian Schütz

-


2016 ◽  
Vol 2016 ◽  
pp. 1-4 ◽  
Author(s):  
Julia Hermes-Laufer ◽  
Lola Del Puppo ◽  
Ihsan Inan ◽  
François-Xavier Troillet ◽  
Omar Kherad

Introduction.Cannabinoid Hyperemesis Syndrome (CHS) is a rare condition that includes cyclic severe vomiting in subjects who have been consuming large doses of cannabis for several years. One of the major diagnostic criteria is the alleviation of symptoms by hot showers. The syndrome was first described in 2004 and is so far neither completely understood nor well known. The latter leads to continued morbidity in concerned subjects and unnecessary expenses for futile investigations. Standard treatments of vomiting as 5-HT3 or D2-receptor antagonists have been shown to be ineffective in alleviating the symptoms. The only long-term satisfying treatment option is the complete abstinence from cannabis consumption.Case Summary.In this case report we describe a 26-year-old male Caucasian long-term cannabis consumer who repeatedly presented in our emergency room with cyclic severe nausea and vomiting ceased by hot showers and resistant to all other treatments. The final diagnosis was not established until his third visit to the ER.Conclusion.CHS is an important differential diagnosis in patients who present with cyclic vomiting and abdominal pain with a history of long-term cannabis use. Recognition of this syndrome is important in order to avoid unnecessary clinical testing and to help the patients break the cycle of drug use.


2019 ◽  
Vol 3 (Reports in Clinical Medicine) ◽  
pp. 1
Author(s):  
Delphine Sidieu ◽  
Allison Gilbert ◽  
Edmond Brasseur ◽  
Alexandre Ghuysen ◽  
Vincent Orio

2015 ◽  
Vol 73 (10) ◽  
pp. 1907-1910 ◽  
Author(s):  
Robert A. Beech ◽  
David R. Sterrett ◽  
James Babiuk ◽  
Henry Fung

Sign in / Sign up

Export Citation Format

Share Document